An interventional study of MyVitalC (ESS60 in Extra Virgin Olive Oil) in Sleep and Headaches, sponsored by Efforia, Inc. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-03-17.
Sponsored by Efforia, Inc · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 324 studies in Headache with a site in United States — 51 open to participants now, 63 under way, 5 of them phase 3. Headache · United States.
Among the 324 studies in Headache with a site in United States, this one is the 95th largest by planned enrollment of the 276 interventional ones that give a count, is one of 17 that started in 2026, is one of 127 with no phase, reaches primary completion later than 28 of the 61 other live ones, and was the 312th registered.
762 studies on the registry are indexed under Headache; 134 are open to participants now.
Browse Headache studies →51 of the 324 studies in Headache with a site in United States are open now. Recruiting first, the newest first:
Salvia BioElectronics · Sites in United States
Ages 22–84
University of Colorado, Denver · Sites in United States
Ages 12–17
Daniel A Tonetti, MD · Sites in United States
Ages 18+
Cortex Neurovascular · Sites in United States
Ages 18–64
Duke University · Sites in United States
Ages 18–60
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 83 Headache studies recruiting now, 30 (36%) set no upper age limit and 44 (53%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
324 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 55 · Phase 3 54 · Phase 4 37
First in 1994; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 65 across 560 interventional studies indexed under Headache.
Median enrollment 64 across the 276 interventional studies, 129 across the 47 observational. Of the 224 that completed or were terminated, 104 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 324 have an industry lead sponsor. The 10 most frequent:
Efforia, Inc is the lead sponsor of 25 studies on the registry; 20 are open to participants now.
Efforia, Inc has 1 study filed under Headache — fewer than ten, so there is no comparison to draw.
19 of the studies in Headache with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06621329Phase 3University of California, DavisTransnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache | 2027-07 |
| NCT07116408Wright State UniversityIntranasal Sphenopalatine Ganglion Blockade for Headaches Following Aneurysmal Subarachnoid Hemorrhage | 2026-11 |
| NCT07309874Texas Tech University Health Sciences CenterEffect of Ultrasound-Guided Dry Needling Targeting Rectus Capitus Posterior Major on Individuals With Headaches | 2026-12-01 |
| NCT07725198Florida Gulf Coast UniversityImmediate Neuromuscular Responses of the Obliquus Capitis Inferior Following Upper Cervical Manual Therapy | 2027-01-01 |
| NCT07054801Daniel Raper, MBBSIA Lidocaine and Methylprednisolone for Headache Associated With Subarachnoid Hemorrhage | 2027-01-01 |
Add all 19 to your calendar (.ics) → With an account.
Among the 324 studies in Headache with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sleep disturbance and recurring headaches can negatively affect daily functioning, mood, and productivity. MyVitalC (ESS60 in extra virgin olive oil) is a commercially available dietary supplement that has generated anecdotal claims related to sleep quality and headache relief; however, human data remain limited.
This real-world observational study is designed to help participants evaluate whether use of MyVitalC is associated with changes in sleep disturbance and headache frequency or severity in their own daily lives. Participants will complete a four-week baseline observation period without the intervention, followed by six weeks of daily MyVitalC use, with weekly self-reported assessments. Participants serve as their own control, allowing for within-person comparison of outcomes before and during product use.
This single-arm observational study uses a structured baseline-plus-intervention design to assess within-participant changes in sleep disturbance and everyday headache outcomes associated with MyVitalC use.
Participants first complete a four-week baseline period during which no study intervention is taken. During this time, participants complete weekly assessments to characterize their typical sleep disturbance and headache patterns. Following baseline, participants begin daily use of MyVitalC for six weeks and continue completing weekly assessments.
The study employs validated patient-reported outcome measures, including the PROMIS Sleep Disturbance Scale and PROMIS Pain Interference Scale, as well as a custom Weekly Headache Check-In. Data will be used to generate individual-level comparisons between baseline and during-use periods. The study is designed as a signal-detection and personal-outcome evaluation trial rather than a randomized controlled efficacy study.
More information can be found at the study recruitment landing page: https://app.efforia.com/myvitalc-sleep-migraine-management/
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single Arm longitudinal where participants act as their own control
Dietary Supplement: MyVitalC (ESS60 in Extra Virgin Olive Oil)
Participants will take 1 teaspoon (5 mL) of MyVitalC, ESS60 in extra virgin olive oil, orally once daily in the morning, with or without food, for six weeks. Daily intake is logged within the study platform.
Change in Sleep Disturbance
Measure: PROMIS Sleep Disturbance Scale Description: Assesses perceived sleep quality, sleep depth, and sleep-related difficulties. Higher scores indicate greater sleep disturbance.
Time frame: Weekly during baseline (4 weeks) and weekly during intervention (6 weeks)
Change in Headache Frequency
Measure: Weekly Headache Check-In (frequency count) Description: Number of headaches experienced in the past 7 days.
Time frame: Weekly during baseline and intervention, and on day 70 (end of study)
Change in Headache Severity
Measure: Weekly Headache Check-In (severity rating) Description: Participant-reported severity of the worst headache experienced during the past 7 days.
Time frame: Weekly during baseline and intervention, and on day 70 (end of study)
Change in Pain Interference
Measure: PROMIS Pain Interference Scale Description: Assesses the extent to which pain interferes with daily activities and functioning.
Time frame: Baseline and day 70 (end of study)
Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.
Of 193 interventional studies with no phase under Headache, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 38. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.